B. Hurst

Discovery of SARS-CoV-2 papain-like protease (PLpro) inhibitors with efficacy in a murine infection model

This study identifies potent SARS-CoV-2 PLpro inhibitors using machine learning, showing efficacy in a mouse model of COVID-19.

Strain dependent structural effects and in vivo efficacy of enterovirus-D68 inhibitors

This study develops a potent EV-D68 inhibitor, 11526092, showing improved in vitro potency and in vivo efficacy compared to pleconaril, with strain-dependent structural effects observed via cryo-EM.

Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against Mpro and cathepsin L

This study determines the structure of SARS-CoV-2 Mpro with calpain inhibitors and analogues, revealing new insights for developing dual inhibitors against Mpro and cathepsin L.

Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture

This study identifies four compounds with broad-spectrum antiviral activity against multiple coronaviruses, including SARS-CoV-2, by inhibiting viral Mpro and cathepsin L.

Rational design of a new class of protease inhibitors for the potential treatment of coronavirus diseases

The paper designs a new class of protease inhibitors targeting coronavirus Mpro, identifying ML1000 as a potent inhibitor with low-nanomolar affinity and antiviral activity.

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

This study identifies inhibitors of SARS-CoV-2 main protease that show potent antiviral activity in cell culture.